(Q44563585)

4 December 2017

title

Anilinopyrazole as selective CDK2 inhibitors: design, synthesis, biological evaluation, and X-ray crystallographic analysis (English)

1 reference

4 December 2017

Jun Tang

1

1 reference

4 December 2017

Lisa M Shewchuk

2

1 reference

4 December 2017

Hideyuki Sato

3

1 reference

4 December 2017

Masaichi Hasegawa

4

1 reference

4 December 2017

Yoshiaki Washio

5

1 reference

4 December 2017

Naohiko Nishigaki

6

1 reference

4 December 2017

language of work or name

English

0 references

publication date

1 September 2003

1 reference

Bioorganic & Medicinal Chemistry Letters

4 December 2017

published in

1 reference

4 December 2017

volume

13

1 reference

4 December 2017

issue

18

1 reference

4 December 2017

page(s)

2985-2988

1 reference

Oncogenic kinase signalling

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900630-9

7 January 2021

The protein kinase complement of the human genome

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900630-9

7 January 2021

Cyclin-Dependent Kinases

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900630-9

7 January 2021

Recent advances in cyclin-dependent kinase inhibition. Purine-based derivatives as anti-cancer agents. Roles and perspectives for the future

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900630-9

7 January 2021

Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and X-ray crystallographic analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900630-9

7 January 2021

Properties and potential-applications of chemical inhibitors of cyclin-dependent kinases

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900630-9

7 January 2021

CDK inhibition and cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900630-9

7 January 2021

The therapeutic potential of targeting the cell cycle

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900630-9

7 January 2021

Structural basis for control by phosphorylation

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900630-9

7 January 2021

Cyclin-dependent kinase inhibitors for treating cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900630-9

7 January 2021

Structure-activity relationship homology (SARAH): a conceptual framework for drug discovery in the genomic era

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900630-9

7 January 2021

10.1016/S0960-894X(03)00630-9

Identifiers

DOI

1 reference

4 December 2017

1 reference